Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
PSMA-based alpha therapy in prostate cancerMike Sathekge, Alfred Morgenstern
Journal of Medical Imaging and Radiation Sciences|August 14, 2019
Development of Targeted Alpha Therapy from Bench to BedsideAlfred Morgenstern, Frank Bruchertseifer
European Journal of Nuclear Medicine and Molecular Imaging|February 20, 2024
Advances in targeted alpha therapy of cancerMike Sathekge, Alfred Morgenstern
Seminars in Nuclear Medicine|March 17, 2020
Supply and Clinical Application of Actinium-225 and Bismuth-213Alfred Morgenstern, Christos Apostolidis, Frank Bruchertseifer
Current Radiopharmaceuticals|December 29, 2011
Targeted alpha therapy with 213BiAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Current Radiopharmaceuticals|May 31, 2012
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopesAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Journal of Labelled Compounds & Radiopharmaceuticals|August 2, 2019
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demandFrank Bruchertseifer, Alban Kellerbauer, Rikard Malmbeck, et al.
Seminars in Nuclear Medicine|April 13, 2016
Targeted Radiolabeled Compounds in Glioma TherapyDominik Cordier, Leszek Krolicki, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2017
The Future of Radioligand Therapy: α, β, or Both?Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2018
New Developments in Peptide Receptor Radionuclide TherapyGuillaume P Nicolas, Alfred Morgenstern, Margret Schottelius, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
PSMA-based alpha therapy in prostate cancerMike Sathekge, Alfred Morgenstern
Journal of Medical Imaging and Radiation Sciences|August 14, 2019
Development of Targeted Alpha Therapy from Bench to BedsideAlfred Morgenstern, Frank Bruchertseifer
European Journal of Nuclear Medicine and Molecular Imaging|February 20, 2024
Advances in targeted alpha therapy of cancerMike Sathekge, Alfred Morgenstern
Seminars in Nuclear Medicine|March 17, 2020
Supply and Clinical Application of Actinium-225 and Bismuth-213Alfred Morgenstern, Christos Apostolidis, Frank Bruchertseifer
Current Radiopharmaceuticals|December 29, 2011
Targeted alpha therapy with 213BiAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Current Radiopharmaceuticals|May 31, 2012
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopesAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Journal of Labelled Compounds & Radiopharmaceuticals|August 2, 2019
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demandFrank Bruchertseifer, Alban Kellerbauer, Rikard Malmbeck, et al.
Seminars in Nuclear Medicine|April 13, 2016
Targeted Radiolabeled Compounds in Glioma TherapyDominik Cordier, Leszek Krolicki, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2017
The Future of Radioligand Therapy: α, β, or Both?Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2018
New Developments in Peptide Receptor Radionuclide TherapyGuillaume P Nicolas, Alfred Morgenstern, Margret Schottelius, et al.
Pageof 18